Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
6.50
+0.39 (6.38%)
At close: Oct 8, 2025, 4:00 PM EDT
6.55
+0.05 (0.77%)
After-hours: Oct 8, 2025, 4:14 PM EDT

Company Description

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.

Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors.

Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Immuneering Corporation
Immuneering logo
CountryUnited States
Founded2008
IPO DateJul 30, 2021
IndustryBiotechnology
SectorHealthcare
Employees66
CEOBenjamin Zeskind

Contact Details

Address:
245 Main Street, Second Floor
Cambridge, Massachusetts 02142
United States
Phone617 500 8080
Websiteimmuneering.com

Stock Details

Ticker SymbolIMRX
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$15.00
CIK Code0001790340
CUSIP Number45254E107
ISIN NumberUS45254E1073
SIC Code2834

Key Executives

NamePosition
Dr. Benjamin J. Zeskind M.B.A., Ph.D.Co-Founder, President, Chief Executive Officer and Director
Robert J. Carpenter M.B.A., M.S.Co-Founder and Chair Emeritus
Dr. Brett M. Hall Ph.D.Chief Scientific Officer
Michael D. Bookman J.D.Chief Legal Officer and Secretary
Mallory Morales CPAPrincipal Financial and Accounting Officer, Chief Accounting Officer and Treasurer
Paula George CPADirector of Accounting and Operations and Assistant Corporate Controller
Leah R. NeufeldChief People Officer
Dr. Peter King Ph.D.Head of Discovery and Vice President
Dr. Praveen Nair Ph.D.Head of Translational Pharmacology and Vice President
Harold E. BrakewoodChief Business Officer

Latest SEC Filings

DateTypeTitle
Oct 7, 2025SCHEDULE 13GFiling
Oct 3, 2025SCHEDULE 13GFiling
Sep 25, 2025424B5Filing
Sep 25, 20258-KCurrent Report
Sep 25, 2025FWPFree Writing Prospectus
Sep 24, 2025FWPFree Writing Prospectus
Sep 24, 2025424B5Filing
Sep 24, 20258-KCurrent Report
Sep 23, 2025144Filing
Sep 9, 2025DNotice of Exempt Offering of Securities